Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2027

Conditions
Pediatric CancersSolid Tumor Pediatric
Interventions
BIOLOGICAL

B7H3-IL7Ra CAR-T cells

Autologous T cells lentiviral transduced to express a B7H3-specific chimeric antigen receptor (CAR) with the addition of an IL-7 receptor alpha signaling domain, administered via central venous access catheter after lymphodepletion

Trial Locations (1)

10330

RECRUITING

King Chulalongkorn Memorial Hospital, Bangkok

All Listed Sponsors
collaborator

King Chulalongkorn Memorial Hospital

OTHER

lead

Chulalongkorn University

OTHER